17α-Pregn-4-en-17β,21-diol-3,20-dione | 601-05-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17α-Pregn-4-en-17β,21-diol-3,20-dione
• 英文别名: 17β,21-dihydroxy-17α-pregn-4-ene-3,20-dione；17alpha-Pregn-4-ene-3,20-dione, 17,21-dihydroxy-；(8R,9S,10R,13S,14S,17S)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 601-05-8
• 化学式: C₂₁H₃₀O₄
• 分子量: 346.467
• InChiKey: WHBHBVVOGNECLV-KWNDPWABSA-N

物化性质

• 沸点：
  524.5±50.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)
• 熔点：
  194-198 °C(Solv: hexane (110-54-3); acetone (67-64-1))

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  炔孕酮 在 [双(三氟乙酰氧基)碘]苯 作用下， 以0.034 g的产率得到17α-Pregn-4-en-17β,21-diol-3,20-dione
  参考文献：
  名称：

  Transformed steroids. 176. Paths of transformation of 17a-ethynyl-17?-hydroxyandrostenes into ?16-21-hydroxy-20-ketopregnenes

  摘要：

  DOI：

  10.1007/bf00962448

文献信息

• Process for the preparation of 21-hydroxy-16-pregnen-20-one derivatives
  申请人：Schering Aktiengesellschaft

  公开号：US04089852A1

  公开（公告）日：1978-05-16

  .DELTA..sup.16 -21-HYDROXY-20-KETO STEROIDS OF THE PREGNANE SERIES HAVING AN OTHERWISE UNSUBSTITUTED D-ring and a 13-methyl or -ethyl group, and 21-ethers and -esters thereof, are produced by reaction of a corresponding D-ring saturated 17-keto steroid with a lithium compound of the formula ##STR1## thereby converting the 17-keto group to a 17.beta.-hydroxy-20.alpha.-enol ether in which the 17.alpha.-side chain has the formula ##STR2## wherein R.sub.3 and R.sub.4 have the values given above, and, in any desired sequence, splitting off R.sub.3 and/or R.sub.4 enol ether by hydrolysis; eliminating 17.beta.-hydroxy group, preferably after acylation, with formation of a .DELTA..sup.16 -double bond; and, if desired, splitting off any blocking group.

  产生具有否则未取代的D环和13-甲基或-乙基基团的孕烷系列的.DELTA..sup.16 -21-羟基-20-酮类固醇，以及它们的21-醚和酯，通过将相应的D环饱和的17-酮类固醇与具有以下公式的锂化合物反应而使17-酮基转化为17β-羟基-20α-烯醚，在其中17α-侧链具有以下公式，其中R.sub.3和R.sub.4具有上述给定的值，并且按任何所需的顺序，通过水解裂解R.sub.3和/或R.sub.4烯醚；在酰化后首选消除17β-羟基，形成.DELTA..sup.16 -双键；如有需要，裂解任何阻断基。
• Cortexolone-17alpha-propionate in crystalline form I
  申请人：Cosmo S.p.A.

  公开号：EP2503004A1

  公开（公告）日：2012-09-26

  The present invention refers to a new enzymatic process for obtaining cortexolone 17α-propionate starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to a new crystalline form of cortexolone 17α-propionate.

  本发明是指一种从相应的 17α，21-二酯开始获得可的松 17α-丙酸酯的酶法新工艺，该工艺包括酶醇解反应。 此外，本发明还涉及一种新的可的松 17α 丙酸酯结晶形式。
• Cortexolone-17alpha-propionate in cristalline hydrate form IV
  申请人：Cosmo S.p.A.

  公开号：EP2503005A2

  公开（公告）日：2012-09-26

  The present invention refers to a new enzymatic process for obtaining cortexolone-17α-propionate starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to a new crystalline form of cortexolone 17α-propionate.

  本发明是指一种从相应的 17α，21-二酯开始获得可的松酮-17α-丙酸酯的酶法新工艺，该工艺包括酶醇解反应。 此外，本发明还涉及一种新的可的松酮-17α-丙酸酯结晶形式。
• 17α,21-diesters of cortexolone for use in the treatment of tumors
  申请人：COSMO TECHNOLOGIES LTD.

  公开号：US10183030B2

  公开（公告）日：2019-01-22

  The present invention provides certain cortexolone derivatives of formula (I) and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products.

  本发明提供了某些式(I)的可的松酮衍生物及其作为抗肿瘤活性成分的用途，用于癌前病变、发育不良、转移瘤和肿瘤疾病（包括恶性肿瘤和转移瘤）的治愈性或辅助性或新辅助性或姑息性治疗。本发明的另一方面涉及包含作为活性成分的式(I)可的松衍生物和至少一种生理上可接受的赋形剂的药物组合物，以及所述药物组合物作为抗肿瘤药物产品的用途。
• Cortexolone 17alpha-benzoate for use in the treatment of tumours
  申请人：COSMO TECHNOLOGIES LTD.

  公开号：US10231980B2

  公开（公告）日：2019-03-19

  The present invention provides certain cortexolone derivatives of formula (I), and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products.

  本发明提供了某些式(I)的可的松酮衍生物，以及其作为抗肿瘤活性成分，用于癌前病变、发育不良、变性和肿瘤疾病（包括恶性肿瘤和转移）的治愈性或辅助性、或新辅助性或姑息性治疗。 本发明的另一方面涉及包含作为活性成分的式(I)可的松衍生物和至少一种生理上可接受的赋形剂的药物组合物，以及所述药物组合物作为抗肿瘤药物产品的用途。